Intravitreal (IVT) injection is a method of delivering medication directly into the eye for the treatment of various eye diseases. Intravitreal injections are commonly used to treat age-related macular degeneration (AMD), diabetic retinopathy, and other retinal disorders. This report will provide an overview of the intravitreal (IVT) injectable market.
Market Size and Growth:
Intravitreal injection is a safe and efficient therapeutic option for retinal diseases such as diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusion, and others. Growing retinal problems are likely to drive the global intravitreal injectable market at a rapid pace throughout the forecast period. The Global Intravitreal (IVT) Injectable Market is estimated to reach $23,814.3 million by 2028, having a CAGR of 4.9%.
Request For Free Sample Report of Intravitreal (IVT) Injectable Market @ https://www.persistencemarketresearch.com/samples/25906
Key Players:
The major players in the intravitreal (IVT) injectable market include Allergan, Novartis AG, Roche, Regeneron Pharmaceuticals, Alimera Sciences, Bayer AG, Bausch Health Companies Inc., Clearside Biomedical, Graybug Vision, and Icon Bioscience, Inc.
Product Types:
Intravitreal (IVT) injectable products are available in various types such as anti-VEGF agents, corticosteroids, antibiotics, and others. Anti-VEGF agents are the most commonly used product type, followed by corticosteroids. Antibiotics and other types of IVT injectable products are used in specific cases.
Applications:
Intravitreal (IVT) injections are commonly used to treat age-related macular degeneration (AMD), diabetic retinopathy, and other retinal disorders. They are also used in the treatment of uveitis, macular edema, and other ocular conditions.
Regional Analysis:
Geographically, North America dominated the intravitreal (IVT) injectable market in 2021, owing to the high incidence of age-related macular degeneration (AMD) and diabetic retinopathy in the region, coupled with the availability of advanced IVT injectable products. However, the Asia Pacific region is expected to witness significant growth during the forecast period due to the increasing healthcare expenditure, growing awareness about ocular diseases, and rising adoption of IVT injectable products in the region.
Conclusion:
The intravitreal (IVT) injectable market is expected to grow significantly during the forecast period due to the increasing incidence of age-related macular degeneration (AMD) and diabetic retinopathy, growing awareness about the benefits of intravitreal injections, and rising adoption of IVT injectable products. Anti-VEGF agents are the most commonly used product type, followed by corticosteroids. North America dominated the market in 2021, while the Asia Pacific region is expected to witness significant growth in the coming years. The major players in the market are Allergan, Novartis AG, Roche, Regeneron Pharmaceuticals, Alimera Sciences, Bayer AG, Bausch Health Companies Inc., Clearside Biomedical, Graybug Vision, and Icon Bioscience, Inc.